Clinical study of KW oral adjuvant immunotherapy for Japanese cedar pollinosis

Clinical study of KW oral adjuvant immunotherapy for Japanese cedar pollinosis - Influence of KW oral adjuvant immunotherapy for Japanese cedar pollinosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007177

Enrollment

Registered

2012-01-31

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar pollinosis

Interventions

It is given the test capsule (50 mg of Lactobacillus strain (KW3110): 1 tablet per day) for 6 months before the beginning of pollen. It is given the placebo tablet (50 mg of placebo: 1 capsule per da

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) CAP-RAST against JCP >= class 2, 2) No clinical history of the Japanese cedar pollenosis

Exclusion criteria

Exclusion criteria: 1) Use of any anti-histamine drugs, anti-allergy drugs, nasal steroid drugs et al at the beginning of the study, 2) Buildup phase of immunotherapy to Japanese cedar pollen, 3) Pregnancy, potential pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Incidence rate of Japanese cedar pollinosis	—

Secondary

Measure	Time frame
Serum anti-Japanese cedar pollen specific IgE antibody, Serum ECP level, Lymphocyte Subsets of Peripheral Blood Mononuclear Cell (Immunophenotyping)	—

Countries

Japan

Contacts

Public ContactShigetoshi Horiguchi

Graduate School of Medicine, Chiba University Department of Otorhinolaryngology, Head and Neck Surgery

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026